SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Tydén Jonas)
 

Sökning: WFRF:(Tydén Jonas) > (2006-2009) > The platelet inhibi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003826naa a2200397 4500
001oai:DiVA.org:uu-24441
003SwePub
008070215s2007 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-244412 URI
024a https://doi.org/10.1016/j.thromres.2006.10.0092 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Alström, Ulricau Uppsala universitet,Institutionen för kirurgiska vetenskaper4 aut0 (Swepub:uu)ulals788
2451 0a The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment
264 1b Elsevier BV,c 2007
338 a print2 rdacarrier
520 a INTRODUCTION: Addition of clopidogrel to patients treated with ASA has been shown to decrease the incidence of in-stent thrombosis after percutaneous coronary interventions. However, it has also been reported that up to 30% of patients do not achieve adequate platelet inhibition from standard dosages of ASA and clopidogrel. There is a demand for reliable methods to measure the individual platelet inhibiting effect of this combination therapy. MATERIALS AND METHODS: The primary aim of the present investigation was to compare three methods for evaluation of the platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thirty patients presenting for coronary angiography/PCI were included. Two patients were excluded due to technical problems. All patients were on 75-100 mg ASA/day for at least 8 days. Blood samples were analysed before and 16 h after a 300 mg clopidogrel bolus dose. The platelet inhibiting effect was measured with (1) Whole blood flow cytometry (17 patients); (2) a bed-side test, Platelet Mapping assay for the thrombelastograph (28 patients); and (3) PFA (Platelet function analyser) -100 (26 patients). RESULTS: With flow cytometry, the percentage of platelets expressing P-selectin (p=0.03) on their surface decreased significantly after the bolus dose of clopidogrel. There was also a reduction of platelets binding fibrinogen when stimulated with ADP. A significantly (p=0.002) increased platelet inhibition could also be demonstrated with Platelet Mapping. PFA-100 could not measure any significant platelet inhibiting effect of clopidogrel. CONCLUSION: A significant platelet inhibition could be demonstrated with flow cytometry and the Platelet Mapping assay, but not with PFA-100. However, levels of response for the individual patient with these three methods were inconsistent. Further studies are needed to evaluate how the results correlate to the clinical risk of thrombosis and bleeding.
653 a Clopidogrel
653 a Flow cytometry
653 a Thrombelastograph
653 a Platelets
653 a PFA-100
653 a MEDICINE
653 a MEDICIN
700a Tydén, Hans4 aut
700a Oldgren, Jonas,d 1964-u Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR),UCR4 aut0 (Swepub:uu)jonaoldg
700a Siegbahn, Agneta,d 1947-u Uppsala universitet,Klinisk kemi4 aut0 (Swepub:uu)agsie424
700a Ståhle, Elisabethu Uppsala universitet,Institutionen för kirurgiska vetenskaper4 aut0 (Swepub:uu)elsta102
710a Uppsala universitetb Institutionen för kirurgiska vetenskaper4 org
773t Thrombosis Researchd : Elsevier BVg 120:3, s. 353-359q 120:3<353-359x 0049-3848x 1879-2472
856u http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17137616&dopt=Citation
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-24441
8564 8u https://doi.org/10.1016/j.thromres.2006.10.009

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy